A Randomized Double-Blind Placebo-Controlled Phase 2b Study Evaluating the Safety and Efficacy of Pirfenidone Solution for Inhalation (AP01) in Subjects with Progressive Pulmonary Fibrosis (PPF)

Brief description of study

The purpose of this study is to evaluate the safety and efficacy of multiple doses of AP01 compared with placebo (a study treatment containing no active ingredients), over 52 weeks in participants with Progressive Pulmonary Fibrosis (PPF). During the study, you will continue your current PPF treatment regimen; the study drug will be added to your current treatment regimen.

Clinical Study Identifier: s23-01605

ClinicalTrials.gov Identifier: NCT06329401

Principal Investigator: Rany Condos.

Other Investigators: John S Munger, Nathaniel Clardy Nelson.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Clinical Research Studies